Cargando…

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice

In IPF, commencement of antifibrotic therapy in patients with preserved lung volume may increase the duration of therapy http://ow.ly/4HeM30lFS67

Detalles Bibliográficos
Autores principales:	Fletcher, Sophie V., Jones, Mark G., Renzoni, Elizabeth A., Parfrey, Helen, Hoyles, Rachel K., Spinks, Katherine, Kokosi, Maria, Kwok, Apollinaris, Warburton, Chris, Titmuss, Vanessa, Thillai, Muhunthan, Simler, Nicola, Maher, Toby M., Brereton, Christopher J., Chua, Felix, Wells, Athol U., Richeldi, Luca, Spencer, Lisa G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2018
Materias:	Original Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194204/ https://www.ncbi.nlm.nih.gov/pubmed/30364342 http://dx.doi.org/10.1183/23120541.00049-2018

Ejemplares similares

Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study
por: Raman, Lavanya, et al.
Publicado: (2023)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Sarcoidosis in the UK: insights from British Thoracic Society registry data
por: Thillai, Muhunthan, et al.
Publicado: (2019)

Quality improvement in Respiratory Medicine: Designing and implementing a bronchoscopy checklist at Southend University Hospital
por: Thillai, Muhunthan, et al.
Publicado: (2013)

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
por: Flaherty, Kevin R., et al.
Publicado: (2022)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
por: Woodcock, Hannah V, et al.
Publicado: (2013)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial
por: Saunders, Peter, et al.
Publicado: (2017)

Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease
por: Jacob, Joseph, et al.
Publicado: (2018)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

PAciFy Cough—a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis Cough
por: Wu, Zhe, et al.
Publicado: (2022)

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021)

Short‐term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis
por: Macaluso, Claudio, et al.
Publicado: (2022)

Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
por: Bonella, Francesco, et al.
Publicado: (2022)

Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics
por: Kolb, Martin, et al.
Publicado: (2023)

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

P249 Predictors of adverse outcome in sarcoidosis complicated by chronic pulmonary aspergillosis
por: Nwankwo, Lisa, et al.
Publicado: (2022)

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
por: Flaherty, Kevin R, et al.
Publicado: (2017)

Health-related quality of life in cardiac sarcoidosis: a systematic review
por: Quijano-Campos, Juan Carlos, et al.
Publicado: (2023)

Defining genetic risk factors for scleroderma-associated interstitial lung disease: IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease
por: Stock, Carmel J. W., et al.
Publicado: (2020)

Functional associations of pleuroparenchymal fibroelastosis and emphysema with hypersensitivity pneumonitis
por: Jacob, Joseph, et al.
Publicado: (2018)

Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique
por: Maher, Toby M., et al.
Publicado: (2015)

Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults
por: Stainer, Anna, et al.
Publicado: (2019)

Personalised medicine in interstitial lung diseases: Number 6 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche
por: Kokosi, Maria A., et al.
Publicado: (2018)

Nintedanib in children and adolescents with fibrosing interstitial lung diseases
por: Deterding, Robin, et al.
Publicado: (2023)

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2019)

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
por: Rinciog, C., et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019)

Bullous pemphigoid associated with nintedanib
por: Hasson, Amelia M., et al.
Publicado: (2019)

Pleuroparenchymal Fibroelastosis. A Review of Clinical, Radiological, and Pathological Characteristics
por: Chua, Felix, et al.
Publicado: (2019)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial
por: Maher, Toby M, et al.
Publicado: (2018)

Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes?
por: Brereton, Christopher J., et al.
Publicado: (2020)

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
por: Seibold, James R, et al.
Publicado: (2020)

The King’s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference
por: Sinha, Aish, et al.
Publicado: (2019)

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2020)

Sarcoidosis and Tuberculosis Cytokine Profiles: Indistinguishable in Bronchoalveolar Lavage but Different in Blood
por: Thillai, Muhunthan, et al.
Publicado: (2012)

Proteomic Analysis of Kveim Reagent Identifies Targets of Cellular Immunity in Sarcoidosis
por: Eberhardt, Christian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8d4jcgupm2tmlim6bnqr5bahu9